JP2008509673A - ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法 - Google Patents

ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法 Download PDF

Info

Publication number
JP2008509673A
JP2008509673A JP2007525837A JP2007525837A JP2008509673A JP 2008509673 A JP2008509673 A JP 2008509673A JP 2007525837 A JP2007525837 A JP 2007525837A JP 2007525837 A JP2007525837 A JP 2007525837A JP 2008509673 A JP2008509673 A JP 2008509673A
Authority
JP
Japan
Prior art keywords
marker
expression
seq
sample
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007525837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509673A5 (enExample
Inventor
ジョン イー． モナハン，
シュブハンギ カマトカー，
セバシュティアン ホールシュ，
ベラ オー． ゴルバチェワ，
カレン グラット，
ドナ フォード，
ウィルソン オー． エンディゲ，
ダスティン エル． アンダーソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2008509673A publication Critical patent/JP2008509673A/ja
Publication of JP2008509673A5 publication Critical patent/JP2008509673A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/99—Racemaces and epimerases (5.1) acting on other compounds (5.1.99)
    • C12Y501/99004—Alpha-methylacyl-CoA racemase (5.1.99.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
JP2007525837A 2004-08-13 2005-08-12 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法 Pending JP2008509673A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60141304P 2004-08-13 2004-08-13
PCT/US2005/028781 WO2006028655A2 (en) 2004-08-13 2005-08-12 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011175448A Division JP2012024089A (ja) 2004-08-13 2011-08-10 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法

Publications (2)

Publication Number Publication Date
JP2008509673A true JP2008509673A (ja) 2008-04-03
JP2008509673A5 JP2008509673A5 (enExample) 2008-09-25

Family

ID=36036805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007525837A Pending JP2008509673A (ja) 2004-08-13 2005-08-12 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法
JP2011175448A Pending JP2012024089A (ja) 2004-08-13 2011-08-10 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011175448A Pending JP2012024089A (ja) 2004-08-13 2011-08-10 ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法

Country Status (7)

Country Link
US (1) US20060068425A1 (enExample)
EP (1) EP1784511A4 (enExample)
JP (2) JP2008509673A (enExample)
KR (1) KR20070052788A (enExample)
CN (2) CN101018874A (enExample)
CA (1) CA2576624A1 (enExample)
WO (1) WO2006028655A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
AU2005245815B2 (en) 2004-05-07 2011-06-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CN1903876B (zh) * 2006-07-10 2010-09-01 郑鸿 一种多肽、编码它的核酸分子及用途
CN101652484B (zh) * 2006-11-08 2013-03-20 密歇根大学董事会 前列腺癌标志物spink1及其应用
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
ATE533861T1 (de) 2007-07-06 2011-12-15 Univ Michigan Mipol1-etv1-gen-neuanordnungen
US20110047634A1 (en) * 2008-02-22 2011-02-24 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of acute lymphoblastic leukemia
KR101018665B1 (ko) * 2008-08-18 2011-03-04 재단법인서울대학교산학협력재단 전립선암 진단 방법 및 장치
ES2495367T3 (es) 2009-04-29 2014-09-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anticuerpos monoclonales de ERG
KR20120036842A (ko) * 2009-05-12 2012-04-18 코닌클리케 필립스 일렉트로닉스 엔.브이. 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
EP3133168B1 (en) * 2009-05-26 2019-01-23 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulations
AU2010295689B2 (en) 2009-09-17 2014-02-13 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
WO2011085002A1 (en) * 2010-01-05 2011-07-14 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
WO2012015765A2 (en) 2010-07-27 2012-02-02 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CN103797120B (zh) * 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
HK1201881A1 (en) 2012-01-31 2015-09-11 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
JP5429725B1 (ja) * 2013-03-22 2014-02-26 独立行政法人理化学研究所 前立腺癌の進行度の評価方法、前立腺癌の検出方法、および検査キット
CA2969154A1 (en) * 2014-12-01 2016-06-09 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel rna-biomarker signature for diagnosis of prostate cancer
ES3007999T3 (en) * 2015-04-21 2025-03-21 Genentech Inc Compositions and methods for prostate cancer analysis
CN109198732A (zh) * 2018-08-20 2019-01-15 苏州晞光生物科技有限公司 一种智能化可穿戴检测人体分泌物的服装及测试方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972170B1 (en) * 1997-12-01 2005-12-06 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
ES2529300T3 (es) * 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
KR100359941B1 (ko) * 2000-04-14 2002-11-07 엘지전자 주식회사 바이오칩 제조방법
DE60231110D1 (de) * 2001-04-02 2009-03-26 Develogen Ag Proteindisulfidisomerase und abc-transporter-homologe proteine, die an der regulierung der energie-homeostase beteiligt sind
US20030138793A1 (en) * 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
AU2003237779B2 (en) * 2002-02-13 2008-06-26 American Diagnostica Inc. Methods for selecting treatment regimens and predicting outcomes in cancer patients
US20040029151A1 (en) * 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
DE10234901A1 (de) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6011015693; Ｃａｎｃｅｒ　Ｒｅｓ．，　（２０００），　６０，　［６］，　ｐ．１６７７-１６８２ *
JPN6011015694; Ｈｏｍｏ　ｓａｐｉｅｎｓ　ａｌｐｈａ-ｍｅｔｈｙｌａｃｙｌ-ＣｏＡ　ｒａｃｅｍａｓｅ　（ＲＭ）　ｍＲＮＡ，　ｃｏｍｐｌｅｔｅ　ｃｄｓ．　［ｏｎｌｉｎｅ］．　２０００-ＦＥＢ-１１　ｕｐｌｏａｄｅｄ． *

Also Published As

Publication number Publication date
JP2012024089A (ja) 2012-02-09
EP1784511A4 (en) 2009-03-11
WO2006028655A2 (en) 2006-03-16
WO2006028655A3 (en) 2006-08-31
EP1784511A2 (en) 2007-05-16
CN101018874A (zh) 2007-08-15
US20060068425A1 (en) 2006-03-30
CA2576624A1 (en) 2006-03-16
CN102680686A (zh) 2012-09-19
KR20070052788A (ko) 2007-05-22

Similar Documents

Publication Publication Date Title
JP2012024089A (ja) ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法
EP1565581B1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
JP2010246558A (ja) 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
US20030108963A1 (en) Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
JP2011092195A (ja) 卵巣癌の同定、評価、予防および治療のための核酸分子およびタンパク質
US20130102482A1 (en) Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
WO2003004989A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002101075A2 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US20030148410A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
WO2002071928A2 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030215805A1 (en) Novel genes, compositions, kits, and methods for identification, assessment prevention, and therapy of breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080811

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080811

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120831

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121010

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121207